Nanobiotix SA (NBTX)
5.33
+0.38
(+7.68%)
USD |
NASDAQ |
Sep 27, 16:00
5.16
-0.17
(-3.19%)
After-Hours: 20:00
Nanobiotix Research and Development Expense (Annual): 41.57M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 41.57M |
| December 31, 2022 | 34.42M |
| December 31, 2021 | 35.94M |
| December 31, 2020 | 27.79M |
| December 31, 2019 | 34.05M |
| December 31, 2018 | 24.67M |
| December 31, 2017 | 20.08M |
| Date | Value |
|---|---|
| December 31, 2016 | 18.72M |
| December 31, 2015 | 15.43M |
| December 31, 2014 | 10.74M |
| December 31, 2013 | 8.003M |
| December 31, 2012 | 5.544M |
| December 31, 2011 | 7.268M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
27.79M
Minimum
2020
41.57M
Maximum
2023
34.75M
Average
34.42M
Median
2022
Research and Development Expense (Annual) Benchmarks
| DBV Technologies SA | 60.22M |
| Cellectis SA | 87.65M |
| Genfit SA | 50.57M |
| Innate Pharma SA | 60.65M |
| Inventiva SA | 119.10M |